OPKMEDIUM SIGNALFINANCIAL10-K

OPK experienced a notable revenue decline while meaningfully reducing operating losses and debt obligations during fiscal 2026.

The company's revenue contraction of nearly 15% suggests operational challenges, but management appears to be actively restructuring by substantially reducing SG&A expenses and debt levels. The reduction in operating losses despite lower revenue indicates effective cost management, though increased R&D spending suggests continued investment in the pipeline.

Comparing 2026-02-26 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

OPK's financial profile shows a mixed but improving picture, with revenue declining to $606.9M while operating losses narrowed meaningfully from $152.1M to $117.4M. The company substantially reduced SG&A expenses by 27% and cut total debt by 21%, demonstrating active balance sheet management. Share buyback activity was reduced by nearly half, likely reflecting capital preservation priorities during this restructuring phase.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
-47.9%
$90.2M$47.0M

Buyback activity reduced 47.9% — capital being redeployed elsewhere or cash conservation underway.

SG&A Expense
P&L
-26.7%
$304.2M$223.0M

SG&A reduced 26.7% — improved cost efficiency or headcount reduction improving operating margins.

Current Liabilities
Balance Sheet
-24%
$193.1M$146.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Accounts Receivable
Balance Sheet
-23.5%
$118.0M$90.3M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Operating Income
P&L
+22.8%
-$152.1M-$117.4M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Total Debt
Balance Sheet
-21.3%
$437.2M$344.0M

Debt reduced 21.3% — deleveraging strengthens balance sheet and reduces financial risk.

Total Liabilities
Balance Sheet
-20.5%
$834.8M$664.0M

Liabilities reduced 20.5% — deleveraging improves balance sheet strength and financial flexibility.

R&D Expense
P&L
+17.9%
$105.2M$124.0M

R&D investment increased 17.9% — signals commitment to future product development, though near-term margin impact.

Inventory
Balance Sheet
+15.9%
$56.8M$65.8M

Inventory built 15.9% — monitor whether demand supports this build or if write-downs may follow.

Revenue
P&L
-14.9%
$713.1M$606.9M

Revenue softened 14.9% — monitor whether this is cyclical or structural.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-03-03
ADDED
As of January 30, 2026 , the registrant had 759,067,256 shares of its common stock, par value $0.01 per share ( Common Stock ) outstanding.
Form 10-K Summary 138 Signatures 139 Certifications EX-21 EX-23.1 EX-31.1 EX-31.2 EX-32.1 EX-32.2 EX-101.
Our pharmaceutical business features NGENLA (somatrogon-ghla), also referred to as Somatrogon (hGH-CTP), a once-weekly human growth hormone injection.
Through our pharmaceutical business, we manufacture and sell Rayaldee , a U.S.
Rayaldee has secured marketing authorizations in 11 European countries, and we are advancing its development in mainland China through our strategic partners.
+7 more — sign up free →
REMOVED
As of January 31, 2025, the registrant had 671,550,270 shares of its common stock, par value $0.01 per share ( Common Stock ) outstanding.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters Item 13.
Form 10-K Summary 123 Signatures 136 Certifications 137 EX-21 EX-23.1 EX-31.1 EX-31.2 EX-32.1 EX-32.2 EX-101.
Our pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection.
Also, through our pharmaceutical division, we manufacture and sell Rayaldee , a U.S.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →